Read your post on IV board.
Given NBIX has no pipeline beyond Elagolix ......... Abbvie buy-out sooner than later.
IMO, after we get 1ST E P3 readout . $25/$30 per share
Sign me up. That would be 3x in 1 yr, give or take. I'm in. :)
Seriously, I do think a buyout is more likely now (not necessarily likely, but more likely). We'll see where we are after December and Kinnect 1, 2 results.